NCT07310849 Digital Care for Holistic Health in Older Adults With Diabetes and Multimorbidity
| NCT ID | NCT07310849 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Chang Gung University of Science and Technology |
| Condition | Type2Diabetes |
| Study Type | INTERVENTIONAL |
| Enrollment | 169 participants |
| Start Date | 2026-05-12 |
| Primary Completion | 2027-06-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 169 participants in total. It began in 2026-05-12 with a primary completion date of 2027-06-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study was to explore the effectiveness of the "Digital Care Community Common Good" program in improving disease control indicators, self-management abilities, depression, and quality of life among patients with comorbidities and type 2 diabetes. The study was designed as a two-year experimental study, with a specific area in New Taipei City selected as the research site. In the first year, the main tasks include establishing an integrated intervention team composed of primary healthcare providers and community resources, expanding the functionalities of the mHealth platform, developing digital educational materials for diabetes comorbidities care, and recruiting and training 6 to 8 community care volunteers. Additionally, 169 eligible participants with type 2 diabetes and comorbidities will be recruited from four communities, completing baseline assessments and randomization into groups. In the second year, a 6-month intervention and effectiveness evaluation of the " Digital Care Community Common Good " program will be implemented. The intervention includes online and in-person educational sessions, telephone care, use of the mHealth platform (featuring educational, data monitoring, contextual learning, interactive, and reminders), as well as home visits, case discussions, and individualized care plans for high-risk cases. Disease control indicators, selfmanagement abilities, depression, and quality of life will be tracked immediately post-intervention, at 3 month, and at 6 month to assess outcomes and changes over time. This study expects to enhance health management for diabetes patients with comorbidities through digital care and interdisciplinary collaboration, offering evidence-based insights and recommendations for policy implementation in the integration of community and primary healthcare models.
Eligibility Criteria
Inclusion Criteria: * Age and Consent: Individuals aged 50 years or older who are willing to provide written informed consent. * Language and Literacy: Participants must be literate and able to communicate in Mandarin or Taiwanese. * Medical Diagnosis: Participants must have a physician-confirmed diagnosis of type 2 diabetes mellitus (T2DM) and at least one comorbid chronic disease (e.g., hypertension, hyperlipidemia, chronic kidney disease, or heart disease). * Technology Use: Participants must own a smartphone and be willing to use the LINE messaging app and web-based health education links. * Residence: Participants must reside within one of the four participating communities and have no plans to move away during the study intervention period. Exclusion Criteria: * Those with severe diabetes-related complications, such as renal failure, cerebrovascular disease, diabetic foot, or retinopathy. * Individuals with psychiatric disorders, undergoing active cancer treatment, or those unable to perform independent self-care (e.g., due to visual impairment or mobility limitations). * Individuals without diabetes but with other chronic diseases. * Individuals residing in long-term care institutions. * Individuals who are simultaneously participating in other intervention programs.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07310849 clinical trial?
This trial is open to participants of all sexes, aged 50 Years or older, studying Type2Diabetes. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07310849 currently recruiting?
Yes, NCT07310849 is actively recruiting participants. Contact the research team at flwu@mail.cgust.edu.tw for enrollment information.
Where is the NCT07310849 trial being conducted?
This trial is being conducted at New Taipei City, Taiwan.
Who is sponsoring the NCT07310849 clinical trial?
NCT07310849 is sponsored by Chang Gung University of Science and Technology. The trial plans to enroll 169 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.